Cargando…

Age-Dependent Impact of Concomitant Radio-Chemotherapy and MGMT Promotor Methylation on PFS and OS in Patients with IDH Wild-Type Glioblastoma: The Real-Life Data

SIMPLE SUMMARY: Nowadays: biological but not chronological age and performance have more influence on decision making by patients with malignant brain tissue tumors. We showed how more aggressive therapy results in the increased life expectancy of older patients with this disease in real life. More...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krigers, Aleksandrs, Klingenschmid, Julia, Cosar, Tolga, Moser, Patrizia, Thomé, Claudius, Freyschlag, Christian F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776384/ https://www.ncbi.nlm.nih.gov/pubmed/36551664 http://dx.doi.org/10.3390/cancers14246180

Ejemplares similares

Surgical Management of Malignant Glioma in the Elderly
por: Klingenschmid, Julia, et al.
Publicado: (2022)

The Clinical Frailty Scale as predictor of overall survival after resection of high-grade glioma
por: Klingenschmid, Julia, et al.
Publicado: (2022)

Same but different. Incidental and symptomatic lower grade gliomas show differences in molecular features and survival
por: Demetz, Matthias, et al.
Publicado: (2023)

The Clinical Frailty Scale as useful tool in patients with brain metastases
por: Kerschbaumer, Johannes, et al.
Publicado: (2022)

Temporal muscle thickness has no prognostic relevance in patients with high-grade glioma compared to functional scales
por: Klingenschmid, Julia, et al.
Publicado: (2023)

Age is associated with unfavorable neuropathological and radiological features and poor outcome in patients with WHO grade 2 and 3 gliomas
por: Krigers, Aleksandrs, et al.
Publicado: (2021)

Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide
por: Brawanski, Konstantin R., et al.
Publicado: (2023)

Impact of GAP-43, Cx43 and actin expression on the outcome and overall survival in diffuse and anaplastic gliomas
por: Krigers, Aleksandrs, et al.
Publicado: (2023)

The Routine Application of Tumor-Treating Fields in the Treatment of Glioblastoma WHO° IV
por: Krigers, Aleksandrs, et al.
Publicado: (2022)

Risk Factors for Radiation Necrosis in Patients Undergoing Cranial Stereotactic Radiosurgery
por: Kerschbaumer, Johannes, et al.
Publicado: (2021)

Mind the gap—the use of sodium fluoresceine for resection of brain metastases to improve the resection rate
por: Kerschbaumer, Johannes, et al.
Publicado: (2022)

Tumor Location Impacts the Development of Radiation Necrosis in Benign Intracranial Tumors
por: Demetz, Matthias, et al.
Publicado: (2023)

Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
por: Teske, Nico, et al.
Publicado: (2021)

Appraisal of re-irradiation for the recurrent glioblastoma in the era of MGMT promotor methylation
por: Kim, Il Han
Publicado: (2019)

Surgeon's comfort: The ergonomics of a robotic exoscope using a head-mounted display
por: Abramovic, Anto, et al.
Publicado: (2021)

Telemedical follow-up in patients after decompressive spine surgery: A retrospective, single center analysis
por: Orban, Christoph, et al.
Publicado: (2022)

Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II
por: Karschnia, Philipp, et al.
Publicado: (2020)

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
por: Yang, Pei, et al.
Publicado: (2015)

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
por: Radke, Josefine, et al.
Publicado: (2019)

The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation
por: Marchi, Francesco, et al.
Publicado: (2020)

Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status()
por: Myung, Jae Kyung, et al.
Publicado: (2014)

XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
por: Le, Nguyen Quoc Khanh, et al.
Publicado: (2020)

Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
por: Chai, Ruichao, et al.
Publicado: (2021)

Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
por: Mareike, Müller, et al.
Publicado: (2021)

Interim PET-CT may predict PFS and OS in T-ALL/LBL adult patients
por: Wang, Liang, et al.
Publicado: (2017)

Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
por: Combs, Stephanie E, et al.
Publicado: (2011)

Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma
por: Schiffgens, Salveena, et al.
Publicado: (2016)

Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
por: Incekara, Fatih, et al.
Publicado: (2020)

Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma
por: Funakoshi, Yusuke, et al.
Publicado: (2021)

Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Peritumoral ADC Values Correlate with the MGMT Methylation Status in Patients with Glioblastoma
por: Ladenhauf, Valentin Karl, et al.
Publicado: (2023)

Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins
por: Singh, Kavita, et al.
Publicado: (2020)

Immune-Related lncRNA Risk Signatures Predict Survival of IDH Wild-Type and MGMT Promoter Unmethylated Glioblastoma
por: Li, Xiaozhi, et al.
Publicado: (2020)

MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas
por: Hosoya, Tomohiro, et al.
Publicado: (2022)

Immunohistochemical Expression of PD-L1 and IDH1 with Detection of MGMT Promoter Methylation in Astrocytoma
por: Hareedy, Amal Ahmed, et al.
Publicado: (2022)

The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma
por: Incekara, Fatih, et al.
Publicado: (2020)

Maintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-Analysis
por: Qian, Xinyu, et al.
Publicado: (2015)

The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents
por: Kurdi, Maher, et al.
Publicado: (2021)

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
por: Lazaridis, Lazaros, et al.
Publicado: (2022)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
por: ABE, Hideaki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p89f9f592pmfe2afhg7tr8oah2